Multiply Labs
Robotic production capacity for the pharma manufacturing industry
About
The traditional manufacturing process for individualized drugs is extremely slow and expensive, because it is based on manual labor. At Multiply Labs, we believe that robotics is the only way to truly scale the production of individualized drugs - finally providing these life-saving therapies to the millions of patients who need them. We develop cloud-controlled modular robotic systems that manufacture individualized drugs, and we deploy these systems in the facilities of our pharma customers. This is pharma robotics as a service: we sell the robotic production capacity that our customers need to scale their next-gen individualized drugs. Multiply Labs is a Y Combinator company (Summer 2016). YC-listed status: Active.
- Website
- multiplylabs.com
- Stage
- series-b+
- Location
- San Francisco, CA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Multiply Labs Robotic Biomanufacturing Platform — Robotic biomanufacturing clusters that automate biologics production inside closed GMP-ready environments, increasing throughput up to 100x at 74% lower cost. · Hardware · Enterprise